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Abstract
Purpose Anorexia is a frequently observed symptom in
patients with cancer and is associated with limited food
intake and decreased quality of life. Diagnostic instru-
ments such as the Anorexia/Cachexia Subscale (A/CS)
of the Functional Assessment of Anorexia/Cachexia
Therapy (FAACT) questionnaire and the visual analog
scale (VAS) for appetite have been recommended in the
assessment of anorexia, but validated cut-off values are
lacking. This study aimed to obtain cut-off values of
these instruments for the assessment of anorexia in pa-
tients with cancer.
Methods The FAACT–A/CS and the VAS for appetite were
administered to patients with cancer before start of
chemotherapy. As reference standard for anorexia, two exter-
nal criteria were used: (1) a cut-off value of ≥2 on the anorexia
symptom scale of the EORTCQLQ C-30 and (2) the question
BDo you experience a decreased appetite?^ (yes/no). ROC
curves were used to examine the optimal cut-off values for
the FAACT–A/CS and VAS.
Resul ts A to ta l o f 273 pa t i en t s (58 % male ;
64.0 ± 10.6 years) were included. The median score
on the FAACT–A/CS was 38 (IQR 32–42) points and
77 (IQR 47–93) points on the VAS. Considering both
external criteria, the optimal cut-off value for the FAAC
T–A/CS was ≤37 (sensitivity (se) 80 %, specificity (sp)
81 %, positive predictive value (PV+) 79 %, negative
predictive value (PV−) 82 %) and for the VAS was ≤70
(se 76 %, sp 83 %, PV+ 80 %, PV− 79 %).
Conclusions For the assessment of anorexia in patients with
cancer, our study suggests cut-off values of ≤37 for the FAAC
T–A/CS and ≤70 for the VAS. Future studies should confirm
our findings in other patient samples.
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Introduction
Anorexia—defined as a loss of appetite—is a symptom with a
high prevalence but often neglected in patients with cancer
[1]. In advanced cancer, anorexia is the 4th most common
symptom after pain, fatigue, and weakness [2].
The prognosis of patients with cancer is adversely
affected by the presence of anorexia as it limits food
intake and, in combination with cancer cachexia, it in-
duces muscle wasting and weight loss, eventually lead-
ing to increased morbidity and mortality [1]. Anorexia
is also inversely associated to quality of life, indepen-
dent of other symptoms [3].
There are several causes for a decreased appetite in
patients with cancer. For example, to be diagnosed with
cancer may result in distress and reduced desire to eat
[4]. Furthermore, an active tumor causes an inflamma-
tory response and changes in hypothalamic function
which have impacts on appetite [1, 5]. Moreover, anti-
tumor treatments such as chemotherapy or radiotherapy
may negatively affect appetite [6].
In order to diagnose anorexia, it is important to have valid
and reliable instruments. For clinical practice, a yes/no ques-
tion (Bdo you experience a decreased appetite^) or anorexia
symptom scale of the quality of life questionnaire of the
EORTC [7] can be used. More recently, two instruments have
been proposed to diagnose anorexia in the definition of cancer
cachexia: the Anorexia/Cachexia Subscale (A/CS) of the
Functional Assessment of Anorexia/Cachexia Therapy
(FAACT) questionnaire [8] and the visual analog scale
(VAS) for appetite but validated cut-off values for these two
instruments are lacking [9, 1]. For example, for the FAACT–
A/CS, a cut-off value of ≤24 has been advised to assess an-
orexia [9] based on the fact that it is the half of the maximum
score than can be obtained. However, as only few pa-
tients were diagnosed with anorexia when using this
cut -off value [10] , the spec ia l in te res t group
BCachexia-Anorexia in Chronic Wasting Diseases^ from
the European Society for Clinical Nutrition and Metab-
olism (ESPEN) consented to a higher cut-off value of
≤30 during its meeting in 2011. However, both pro-
posed cut-off values have not been validated. For the
VAS for appetite, studies have used cut-off values of
<50 [11] and <70 [12], but objective support is also
lacking for these cut-off values.
Therefore, the aim of this study was to provide empirical
evidence for cut-off values for the FAACT–A/CS and the VAS
to assess anorexia in patients with cancer.
Materials and methods
Participants
This cross-sectional study consisted of patients with advanced
cancer scheduled for a new chemotherapy treatment. Adult pa-
tients with diagnosis of breast/colorectal/lung/prostate cancer
were invited to enter the study before start of treatment with
chemotherapy. Patients who had received chemotherapy during
the last month and thosewith insufficient command of theDutch
language were excluded. The patients were recruited from Oc-
tober 2011 to March 2014 from the departments of Medical
Oncology and Pulmonology at the VUUniversityMedical Cen-
ter in Amsterdam, The Netherlands. The research protocol was
approved by the Medical Research and Ethics Committee and
informed consent was obtained from all participants.
Measures of anorexia
In order to examine anorexia, patients were asked to fill out
the FAACT–A/CS (4th version, Dutch) and the VAS for ap-
petite before start of chemotherapy treatment. These instru-
ments were presented to the patients on paper and assistance
was offered if required. Both instruments were filled out based
on the patients’ experience regarding their appetite during the
last 7 days.
The 12 items of the FAACT–A/CS [8] were scored on a
five-point Likert scale (0 = not at all, 1 = a little bit, 2 = some-
what, 3 = quite a bit, and 4 = very much) (Fig. 1). The scores
of negatively worded items were reversed. The sum score
ranges from 0 to 48, whereby a lower score indicates less
appetite. For scoring the FAACT–A/CS, the FACIT manual
was applied [13].
The VAS for appetite is a 100-mm line in which the ex-
tremities were anchored by BI had no appetite at all^ (0 mm)
and BMy appetite was very good^ (100 mm) (Fig. 2). The
VAS score for anorexia was obtained by measuring the dis-
tance inmillimeter from the anchor BI had no appetite at all^ to
the point drawn by the patient. Again, lower scores point to
less appetite.
External criteria for anorexia assessment
At present, no gold standard exists to diagnose anorexia in
patients with cancer. Therefore, two external criteria with high
face validity were used as reference method in order to deter-
mine the optimal cut-off values of the FAACT–A/CS and the
VAS. The first external criterion was the anorexia symptom
scale of the European Organization for Research and Treat-
ment of Cancer (EORTC) Quality of Life Questionnaire
(QLQ)-C30 (3rd version) [7] which consists of one item that
assesses appetite: BHave you lacked appetite?^ The responses
are scaled on a four-point Likert scale (1 = not at all, 2 = a
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little, 3 = quite a bit, and 4 = very much). A cut-off value of ≥2
on the anorexia symptom scale was used to assess anorexia,
because the response option Ba little^ indicates that patients
experience their appetite to be different from normal (in con-
trast to the response option Bnot at all^). The second external
criterion which was used in order to assess anorexia is a fre-
quently asked question in clinical practice: BDid you have a
decreased appetite during the last month?^ The response op-
tion for this question was dichotomous: yes/no.
Statistical analysis
Descriptive statistics were used to describe the patient popu-
lation regarding their age, sex, and type of cancer. Means and
standard deviations or medians and interquartile range were
calculated for quantitative patient characteristics as well as for
the scores of the FAACT–A/CS and the VAS for appetite.
Absolute numbers and frequencies were presented for nomi-
nal data.
In order to examine the optimal cut-off values for the
FAACT–A/CS and the VAS for appetite, receiver operating
characteristic (ROC) curves were assessed with the two
external criteria as reference standard. In these ROC plots,
the true positive rate (sensitivity) was plotted against the false
positive rate (1−specificity) over a range of cut-off values.
Perfect discrimination of a test is obtained when the ROC
curve passes through the upper left corner (100 % sensitivity,
100 % specificity). The optimal cut-off values for the FAAC
T–A/CS and the VAS for appetite were determined by the
overall smallest percentage of false positives and false nega-
tives. The sensitivity and specificity for these cut-off values
were obtained by the ROC curves analysis. In addition, the
positive and negative predictive values were calculated. Due
to the use of two external criteria, two cut-off values were
obtained for both instruments. The cut-off value correspond-
ing with the highest predictive value was chosen.
The analyses were carried out using SPSS software, ver-
sion 20 (2011, IBM Corporation, Armonk, NY, USA).
Results
Three hundred and fourteen patients were invited to partici-
pate in this study and 273 patients participated (Fig. 3). The
Fig. 1 The Anorexia/Cachexia
Subscale of the FAACT
questionnaire [13]
Fig. 2 The visual analog scale
(VAS) for appetite
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participants had a mean age of 64.0 ± 10.6 years; 58 % of the
patients were male and the most common type of cancer in
this study population was lung cancer (Table 1).
The median score on the FAACT–A/CS was 38 (IQR 32–
42) points and 77 (IQR 47–93) points on the VAS for appetite.
The median scores of the FAACT–A/CS and the VAS for the
different response categories of both external criteria are pre-
sented in Table 2. A gradual decline in the median scores of
the FAACT–A/CS and the VAS was noticeable for the re-
sponse options Bnot at all^ to Bvery much^ of the anorexia
symptom scale of the EORTCQLQ C-30. Comparing the two
external criteria shows that the median score was 41 points for
the FAACT–A/CS for the option Bnot at all^ of the anorexia
symptom scale of the EORTC QLQ C-30 and also for the
option Bno^ of the clinical practice question. For the VAS,
the median score was 90 points for Bnot at all^ on the EORTC
QLQ C-30 compared to 88 points for Bno^ of the clinical
practice question (Table 2). Median scores on the FAACT–
A/CS were different in patients with breast cancer (lower, 34
points (IQR 30–39)) and colorectal cancer (higher, 40 (IQR
36–43)) compared to patients with prostate and lung cancer
(38 (IQR 32–41) and 37 (IQR 30–41) respectively). This was
also the case for VAS scores: breast cancer (lower, 51 (IQR
41–78), colorectal cancer (higher, 87 (IQR 64–96) compared
to prostate cancer and lung cancer (73 (IQR 48–92 and 72
(IQR 41–91), respectively).
The optimal cut-off values for the FAACT–A/CS were ≤37
and ≤38 according to the external criteria EORTC QLQ C-30
and the decreased appetite question, respectively. For the VAS
for appetite, the optimal cut-off values were ≤70 and ≤72
according to the external criteria EORTC QLQ C-30 and the
decreased appetite question, respectively. The cut-off values
of ≤37 on the FAACT–A/CS and ≤70 on the VAS had the
highest predictive values (Table 3); therefore, these cut-off
values are suggested for the assessment of anorexia in patients
with cancer. The sensitivity, specificity, positive predictive
value (PV+), and negative predictive value.
(PV−) for these cut-off values are presented in Table 3.
Discussion
The results of this study reveal that using two external criteria,
the optimal cut-off value to assess anorexia is ≤37 for the
FAACT–A/CS and ≤70 for the VAS for appetite. This indi-
cates that the currently used cut-off values for the FAACT–A/
CS and the VAS for appetite are too low, leaving many per-
sons with a lack of appetite undetected. The obtained cut-off
value of ≤37 for the FAACT–A/CS is substantially higher
than the currently used cut-off value of ≤24 [9] and even
higher than the more recently proposed cut-off value of ≤30.
This suggests that dividing the maximum attainable sum score
of 48 points by half is inappropriate to examine anorexia in
patients with cancer. In another study in patients with lung
cancer, mean scores of the FAACT–A/CS were higher in pa-
tients with weight loss (37.2 ± 6.5) compared to patients with-
out weight loss (33.1 ± 7.7, p = 0.01) [14], but in both groups,
Fig. 3 Flowchart
Table 1 Patient characteristics (n = 273)
Characteristic Number (%)
Male/female ratio 158/115 (58/42)
Age in years 64.0 ± 10.6a
Cancer type
Breast (stage IV) 34 (13)
Prostate (stage IV) 50 (18)
Colon/rectal (stage IV) 78 (29)
Lung (stage II–IV) 111 (41)
Treatment line
1st line 205 (75)
2nd line 41 (15)
Higher than 2nd line 27 (10)
Treatment in 6 months before inclusion
Surgery 39 (14)
Chemotherapy 51 (19)
Targeted therapy 22 (8)
Hormonal therapy 58 (21)
Presence of brain metastases 24 (9)
a Data presented as mean ± SD
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mean scores were >30. For the VAS for appetite, the proposed
cut-off value of <70 [12] corresponds with the findings in our
study, which implies that the cut-off value of <50 [11] might
underestimate the prevalence of anorexia in patients with
cancer.
In order to examine the cut-off values for the FAACT–A/
CS and the VAS for appetite to assess anorexia in patients with
cancer, the optimal cut-off values were calculated using ROC
curves and defining the optimal cut-off point as the point with
the smallest summed percentages of misclassification. This
implies that the false negative classifications (missed patients
with loss of appetite) and false positive misclassifications (pa-
tients unjustly classified as having loss of appetite) were ap-
preciated equally.
We made use of two external criteria because a gold stan-
dard to assess anorexia is lacking. Studies that assessed an-
orexia instruments have usually looked at correlations with
food intake [15, 16], performance status [8], and functional
and clinical outcomes [16]; however, there may be a lot of
confounding factors using these variables. For example, food
intake may not only be hampered due to anorexia but also due
to dysphagia or chewing problems. Correlation between food
intake and desire to eat was low according to Parker et al [15]:
Pearson’s r was 0.38 at the highest. Arezzo di Trifiletti et al.
[16] found no significant correlation between VAS appetite
and food intake and VAS appetite and body weight and a
low correlation between the FAACT and food intake
(r = 0.46) and FAACT and BMI (r = 0.40). We have chosen
the EORTC QLQ C-30 as an external criterion for its avail-
ability of reference values for the anorexia symptom scale in a
general, healthy population from Germany, Norway, Austria,
Denmark, and the USA [17]. Of the 7802 healthy subjects,
86% scored Bnot at all,^ 10% Ba little,^ 3% Bquite a bit,^ and
1 % Bvery much.^ It is debatable what should be considered a
loss of appetite. According to our opinion, patients who indi-
cate that they have lacked their appetite Ba little^ imply that
they have at least some problems with their appetite. This idea
was supported by the reference values of the general popula-
tion because 86 % of healthy subjects indicated no problems
with appetite at all. Therefore, a cut-off value of ≥2 on the
anorexia symptom scale of the EORTC QLQ C-30 was used
in this study to assess anorexia. However, when one would
consider a cut-off value of ≥3 (Bquite a bit^ and Bverymuch^),
the optimal cut-off values would be ≤34 for the FAACT–A/
CS and ≤59 for the VAS for appetite in our study population.
These cut-off values are lower than the cut-off values we pro-
pose (≤37 for the FAACT–A/CS and ≤70 for the VAS for
appetite), but still higher than those currently used. As second
external criteria, we used the question BDid you have a de-
creased appetite during the lost month,^ since it is frequently
used in clinical practice and easy for patients to answer. Our
study showed that the optimal cut-off values for the FAACT–
A/CS and the VAS were comparable for the two external
criteria we used.
We here present for the first time cut-off values for the
FAACT–A/CS and the VAS for appetite, two instruments rec-
ommended for the assessment of anorexia in the diagnosis of
the cancer anorexia-cachexia syndrome [9]. This study indi-
cates that the optimal cut-off values for assessing anorexia in
Table 2 Median scores of the
FAACT–A/CS and the VAS for
appetite for the response
categories of the external criteria
External criteria FAACT–A/CS (0–48)
median (IQR)
VAS for appetite (0–100)
median (IQR)
EORTC QLQ C-30: BHave you lacked appetite?^
Not at all (n = 141) 41 (38–43) 90 (77–96)
A little (n = 74) 36 (33–38) 62 (42–80)
Quite a bit (n = 33) 29 (25–33) 41 (29–50)
Very much (n = 20) 22 (17–26) 8 (3–23)
BDid you have a decreased appetite during the last month?^
No (n = 153) 41 (37–43) 88 (73–96)
Yes (n = 115) 33 (27–37) 49 (33–72)
FAACT functional assessment of anorexia/cachexia therapy, A/CS Anorexia/Cachexia Subscale, VAS visual
analog scale, EORTC QLQ European Organization for Research and Treatment of Cancer Quality of Life
questionnaire
Table 3 Cut-off values of the FAACT–A/CS and the VAS for appetite
with their corresponding sensitivity, specificity, and predictive values
Se (%) Sp (%) PV+ (%) PV− (%)
FAACT–A/CS ≤ 37a 80 81 79 82
FAACT–A/CS ≤ 38b 85 69 67 86
VAS ≤ 70a 76 83 80 79
VAS ≤ 72b 76 76 70 81
FAACT-A/CS Anorexia/Cachexia Subscale (A/CS) of the Functional As-
sessment of Anorexia/Cachexia Therapy, VAS visual analog scale, Se
sensitivity, Sp specificity, PV+ positive predictive value, PV− negative
predictive value
a Determined by external criterion EORTC QLQ C-30
bDetermined by external criterion decreased appetite question
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patients with cancer might be higher (≤37 for the FAACT–A/
CS and ≤70 for the VAS for appetite) than the currently used
cut-off values (≤24 or ≤30 for the FAACT–A/CS and <50 for
the VAS for appetite). Future studies should confirm our find-
ings in other patient samples.
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